Jardiance, Invokana, and other SGLT2 inhibitors for diabetes treatment may eventually be used to treat and prevent heart failure and kidney disease in people without diabetes, Thomas Reinke reports in the current issue of Managed Care.
There are the big "ifs," though, of positive results from ongoing clinical trials and then FDA approval.
Reinke also reports that advent of SGLT2 inhibitors as diabetes medications is not without drawbacks. They have complicated regimens and ratcheted up costs.
The FDA has already expanded the indications for Jardiance (empagliflozin) and Invokana (canagliflozin) for people with diabetes, Reinke, a contributing editor, reports. Jardiance was approved for reducing cardiovascular death while Invokana received broader approval for reducing cardiovascular death, nonfatal heart attacks, and nonfatal stroke.
"Now the manufacturers of the three SGLT2 inhibitors [a class that includes Farxiga (dapaglifozin)] are pursuing indications that expand the use of these medications to people without diabetes," Reinke says his Medication Management column in the July-August issue.